Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
about
Virus encoded circulatory miRNAs for early detection of prostate cancerChemotherapy options in castration-resistant prostate cancerAbiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utilityPredicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer: A meta-analysis of randomized trialsBone-Targeted Imaging and Radionuclide Therapy in Prostate CancerFOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.KLF5 promotes apoptosis induced by phorbol ester as an effector of the autocrine factor TNFα in LNCaP prostate cancer cells.Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancerWords of wisdom. Re: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agentsDifferential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials.Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.
P2860
Q26776424-3101BA1A-C4C7-4816-8E74-A9710097254AQ28078477-EB284CA3-F999-4E1B-A766-28E94934167DQ33656820-CF56E0FB-A167-4E73-AD85-3650EEDF5E44Q36113762-F94AA52E-7680-433F-AE38-3CBD0E8615E6Q36175852-55AF3980-B306-461D-B6B8-33874A631715Q37390666-E40322EC-9BFE-407B-8272-B1E38204CF32Q38286227-A3F416D1-3D71-4343-A3DA-C6640E17448CQ38633660-7D7BCBE8-F420-4177-BC1D-AFB2043CA49FQ38799217-4B3091B5-C0E8-4DEE-AF15-EC4FA250BF4EQ38958184-A28EC14F-B147-41CB-BF9F-DC5F2F0D7C77Q41990085-BDCBEC7E-C6FE-4F85-9F73-73DAC0042BB9Q47162505-1567F5B0-B105-4728-B42B-42B95A53759AQ47685684-76399E25-F387-425D-BF55-D206A4A4D848Q55380001-52E005B4-050D-468E-943B-13EF170FF244
P2860
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Metastatic castration-resistan ...... ial use of novel therapeutics.
@en
type
label
Metastatic castration-resistan ...... ial use of novel therapeutics.
@en
prefLabel
Metastatic castration-resistan ...... ial use of novel therapeutics.
@en
P2093
P2860
P1476
Metastatic castration-resistan ...... ial use of novel therapeutics.
@en
P2093
Ali Shamseddine
Aurelius Omlin
Carmel Pezaro
Deborah Mukherji
Johann de Bono
P2860
P2888
P304
P356
10.1007/S10555-013-9473-1
P577
2014-09-01T00:00:00Z
P6179
1003695905